FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely, to haematology, and can be used for treating thrombocytopenia in children with Wiskott-Aldrich syndrome. Method involves monitoring the haemogram and the biochemical blood test, wherein medication-based therapy is given with a thrombopoietin receptor agonist (TPO-RA) eltrombopag at a daily dosage of 2 to 3 mg/kg in the period before haematopoietic stem cell transplantation for at least 4 weeks without correcting the dosage.
EFFECT: possibility of preventing life-threatening haemorrhages without causing infectious complications in children with Wiskott-Aldrich syndrome in the period before haematopoietic stem cell transplantation.
1 cl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING IMMUNE THROMBOCYTOPENIA | 2018 |
|
RU2703458C1 |
| TEST SYSTEM AND METHODS OF DETERMINING BIOLOGICAL ACTIVITY OF HUMAN THROMBOPOETIN RECEPTOR AGONISTS | 2023 |
|
RU2810503C1 |
| METHOD FOR CORRECTION OF AMEGAKARYOCYTIC THROMBOCYTOPENIA | 2012 |
|
RU2519745C2 |
| GDF-15 AS A HAEMATOLOGICAL TOXICITY BIOMARKER | 2016 |
|
RU2741390C2 |
| SOLID DOSAGE FORM OF AVATROMBOPAG AND METHOD FOR PRODUCTION THEREOF | 2020 |
|
RU2769863C1 |
| LOW-VOLUME METHOD FOR EXTRACORPOREAL PHOTOCHEMOTHERAPY | 2021 |
|
RU2791659C1 |
| METHOD FOR THE TREATMENT OF THROMBOCYTOPENIA IN CORONAVIRUS INFECTION | 2022 |
|
RU2783888C1 |
| METHOD FOR REDUCING TOXIC AND INFECTIOUS COMPLICATIONS IN THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA | 2020 |
|
RU2773740C2 |
| METHOD OF MAXILLARY SINUS PUNCTURE | 2018 |
|
RU2702459C1 |
| METHOD OF PRODUCING AVATROMBOPAG | 2019 |
|
RU2709496C1 |
